Tune Therapeutics: Can Epigenome Editing Cure...
CMN Interview
Mar. 4, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Tune Therapeutics
Company type: Therapeutics
Main focus: Epigenetically-modified cell therapy
Company stage: Pre-clinical
Diseases: Various
Genome-editing tool: CRISPR-based epigenome editing
Funding stage: Series B
Location: Seattle and Durham, USA
Website: https://tunetx.com
Pipeline: Not disclosed
Partners:
Tune Therapeutics is a pre-clinical stage company focused on the development of new therapeutics based on CRISPR-Cas epigenome editors. Epigenome editing allows for fine-tuning of gene expression ( up-regulation and/or down-regulation) without the risks associated with permanent genomic edits. As of June 2023, Tune Therapeutics is advancing proof-of-concept studies showcasing its technology, the latest being stable down-regulation of the PCSK9 gene in non-human-primates.
